Table 2.

Cox proportional hazard analyses of four prognostic lipoproteins (full list of primary analyses are given in the online supplementary table S3), and secondary analyses with known prognostic factors, principal lipoprotein classes and CRP

	Discovery cohort			Validation cohort
	HR	95% CI	P values	HR	95% CI	P values
	Primary analysis: adjusted for age, diuretic treatment and atrial fibrillation
HDL-4-Apo A-2	0.48	0.33 to 0.7	1.35×10–4	0.6	0.43 to 0.84	2.67×10–3
HDL-4-Apo A-1	0.51	0.35 to 0.73	2.41×10–4	0.62	0.46 to 0.85	3.03×10–3
HDL-4-phospholipids	0.54	0.38 to 0.76	3.75×10–4	0.61	0.44 to 0.84	2.33×10–3
	Secondary analysis: adjusted for 6MWD and NT-proBNP
HDL-4-Apo A-2	0.55	0.36 to 0.84	6.03×10–3	0.61	0.43 to 0.86	5.18×10–3
HDL-4-Apo A-1	0.63	0.42 to 0.96	3.29×10–2	0.65	0.47 to 0.92	1.38×10–2
HDL-4-phospholipids	0.63	0.42 to 0.94	2.38×10–2	0.64	0.46 to 0.89	7.91×10–3
	Secondary analysis: adjusted for HDL cholesterol, LDL cholesterol and CRP
HDL-4-Apo A-2	0.57	0.39 to 0.84	4.53×10–3	0.54	0.34 to 0.86	9.32×10–3
HDL-4-Apo A-1	0.60	0.40 to 0.90	1.41×10–2	0.53	0.33 to 0.85	8.28×10–3
HDL-4-phospholipids	0.61	0.41 to 0.91	1.53×10–2	0.51	0.32 to 0.82	5.03×10–3

Apo, apolipoprotein; CI, confidence interval; CRP, C reactive protein; HDL, high-density lipoprotein; HR, hazard ratio; LDL, low-density lipoprotein; 6MWD, 6 min walk distance; NT-proBNP, N-terminal pro-brain natriuretic peptide.